Using Cox proportional hazards modeling that incorporated transfusion as a time-dependent covariate and adjusted for baseline characteristics, bleeding, transfusion propensity, and nadir hematocrit, transfusion was associated with an increased hazard for 30-day death (adjusted hazard ratio [HR], 3.94; 95% confidence interval [CI], 3.26 4.75) and 30-day death/MI (HR, 2.92; 95% CI, 2.55 3.35).
When we directly compared DVT and bleeding in the propensity score-matched fondaparinux- and enxoparin-treated groups, we found that, compared with enoxaparin, fondaparinux reduced the risk of DVT but increased the risk of major bleeding.
Treatment with UFH is challenging in surgical patients due to their high propensity for bleeding.
When large (over 4 cm) they have a higher propensity to bleeding, and secondary to even minor trauma, can lead to intratumoral or retroperitoneal hemorrhage [1], rarely intraperitoneal hemorrhage [2], and ultimately hemorrhagic shock.
Co-medication with warfarin and parecoxib has been shown to increase the propensity to bleeding [ 38].
Similarly, the propensity to bleeding in ARC syndrome secondary to the documented platelet abnormalities was another important consideration in making such decisions.
Soft tissue removal is a common challenge in rhinologic surgery, owing to the propensity for bleeding from tissues such as adenoids, polyps, and tumors.
Antithrombotic therapy is a critical portion of the treatment regime for a number of life-threatening conditions, including cardiovascular disease, stroke, and cancer; yet, proper clinical management of anticoagulation remains a challenge because existing agents increase the propensity for bleeding in patients.
Patients with CCM have loss‐of‐function mutations in one of the three CCM‐encoding genes (CCM1, CCM2, or CCM3) that result in formation of enlarged and irregular blood vessels with high propensity to bleeding leading to seizures and strokes (Fischer et al, 2013).
